医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Qingdao Primedicine Pharmaceutical Co. Ltd and Primary Peptides Inc. Announce Exclusive China Partnership

2020年05月19日 PM10:00
このエントリーをはてなブックマークに追加


 

QINGDAO, China & VANCOUVER, British Columbia

Qingdao Primedicine Pharmaceutical Co. Ltd., a leading biotech company in China, and Primary Peptides Inc, a privately held biotech company in Canada, today announced an exclusive license to develop and commercialize an innovative product for the treatment of heart attack.

Under the terms of the agreement, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.

“Primedicine is pleased to collaborate with Primary Peptides, a world leader in development of novel peptide therapeutics”, commented Yi Yan, CEO of Primedicine, “This gives Primedicine a valuable opportunity to bring the best Canadian technology to China to improve the lives of millions of heart attack patients.”

Dr. Max Cynader, CEO of Primary Peptides said “Heart protection following heart attack represents a large unmet medical need, and this new peptide therapeutic has the potential to become a first-in-class therapeutic. By combing our expertise in drug development and Primedicine’s abundant Chinese resources, we can bring this novel peptide therapeutic from bench to bedside at a much faster speed”.

Editor’s Notes

About Qingdao Primedicine Pharmaceutical Co. Ltd

Qingdao Primedicine Pharmaceutical Co. Ltd is a leading Chinese biotech company with a major focus on first-in-class drugs. It has cutting-edge products in addiction, Alzheimer’s disease, stroke, depression and several other severe disease indications. For more information, please visit: http://www.primedicine.com

About Primary Peptides Inc.

Primary Peptides is a clinical-stage biotech company that has developed a proprietary ​platform technology enabling it to identify, target, and disrupt specific protein-protein ​interactions. Our peptides can also replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision. Primary Peptides has developed lead compounds in several disease indications with unmet medical needs. ​

For more information, please visit: www.primarypeptides.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005036/en/

CONTACT

Name: Yi Yan

Phone: 86-18661907889

Email: yyan@primedicine.com

or

Name: Max Cynader

Phone: 1-604-649-2274

Email: max@primarypeptides.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Doctor Anywhere Chooses Vonage to Power Telehealth Services in Southeast Asia
  • CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
  • PCI Pharma Services宣布在新英格兰投资1亿美元进行重大生产扩张,为客户提供全球产能
  • PCIファーマ・サービシズがニューイングランド施設に1億ドルを投じ、大規模な生産拡張により顧客に世界的能力を提供すると発表
  • Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO